Thioredoxin and related molecules - From biology to health and disease

Antioxidants and Redox Signaling

Volumn 9, Issue 1, 2007, Pages 25-47

  Lillig, Christopher Horst ^a   Holmgren, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHEMOKINE; CYTOKINE; GLUTAREDOXIN; GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN BINDING PROTEIN; THIOREDOXIN REDUCTASE;

AGING; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BACTERIAL INFECTION; BRAIN ISCHEMIA; CANCER; CARDIOVASCULAR DISEASE; CELL DEATH; DEGENERATIVE DISEASE; DIABETES MELLITUS; EMBRYO DEVELOPMENT; INFLAMMATORY CELL; METABOLISM; OXIDATION REDUCTION REACTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTOZOAL INFECTION; REPRODUCTION; RETINITIS PIGMENTOSA; REVIEW; SIGNAL TRANSDUCTION; TESTIS; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; THIOREDOXIN; TISSUE DISTRIBUTION;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 33845428642     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.9.25     Document Type: Review

References (281)

1. Ahsan MK, Masutani H, Yamaguchi Y, Kim YC, Nosaka K, Matsuoka M, Nishinaka Y, Maeda M, and Yodoi J. Loss of interleukin-2-dependency in HTLV-1-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene 25: 2181-2191, 2006.
2. Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J, and Shigesada K. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues. J Biol Chem 272: 14497-14500, 1997.
3. Akterin S, Cowburn RF, Miranda-Vizuete A, Jimenez A, Bogdanovic N, Winblad B, and Cedazo-Minguez A. Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ 13: 1454-1465, 2006.
4. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10 Suppl: S18-25, 2004.
5. Andricopulo AD, Akoachere MB, Krogh R, Nickel C, McLeish MJ, Kenyon GL, Arscott LD, Williams CH Jr, Davioud-Charvet E, and Becker K. Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett 16: 2283-2292, 2006.
6. Anestål K and Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278: 15966-15972, 2003.
7. Arnér ESJ and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
8. Asahi T, Bandurski RS, and Wilson LG. Yeast sulfate-reducing system. II. Enzymatic reduction of protein disulfide. J Biol Chem 236: 1830-1835, 1961.
9. Asahina M, Yamada T, Yoshiyama Y, and Yodoi J. Expression of adult T cell leukemia-derived factor in human brain and peripheral nerve tissues. Dement Geriatr Cogn Disord 9: 181-185, 1998.
10. Ashley RH. Challenging accepted ion channel biology: p64 and the CLIC family of putative intracellular anion channel proteins. Mol Membr Biol 20: 1-11, 2003.
11. Aslund F, Berndt KD, and Holmgren A. Redox potentials of glutaredoxins and other thiol-disulfide oxidoreductases of the thioredoxin superfamily determined by direct protein-protein redox equilibria. J Biol Chem 30780-30786, 1997.
12. Bai J, Nakamura H, Hattori I, Tanito M, and Yodoi J. Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci Lett 321: 81-84, 2002.
13. Bai J, Nakamura H, Kwon YW, Hattori I, Yamaguchi Y, Kim YC, Kondo N, Oka S, Ueda S, Masutani H, and Yodoi J. Critical roles of thioredoxin in nerve growth factor-mediated signal transduction and neurite outgrowth in PC12 cells. J Neurosci 23: 503-509, 2003.
14. Bandyopadhyay S, Starke DW, Mieyal JJ, and Gronostajski RM. Thioltransferase (glutaredoxin) reactivates the DNA-binding activity of oxidation-inactivated nuclear factor 1. J Biol Chem 273: 392-397, 1998.
15. Becker K, Gromer S, Schirmer RH, and Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 267: 6118-6125, 2000.
16. Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, and Ginsburg H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol 34: 163-189, 2004.
17. Benham AM. Oxidative protein folding: an update. Antioxid Redox Signal 7: 835-858, 2005.
18. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466, 1996.
19. Berggren MM, and Powis G. Alternative splicing is associated with decreased expression of the redox proto-oncogene thioredoxin-1 in human cancers. Arch Biochem Biophys 389: 144-149, 2001.
20. Berglund O. Identification of a thioredoxin induced by bacteriophage T4. J Biol Chem 244: 6306-6308, 1969.
21. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Paglici S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Herzenberg LA, and Ghezzi P. Thioredoxin a redox enzyme released in infection and inflammation is a unique chemoattractant for neutrophils monocytes and T cells. J Exp Med 189: 1783-1789, 1999.
22. Bharath S, Hsu M, Kaur D, Rajagopalan S, and Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64: 1037-1048, 2002.
23. Bizzarri C, Holmgren A, Pekkari K, Chang G, Colotta F, Ghezzi P, and Bertini R. Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin. Antioxid Redox Signal 7: 1189-1194, 2005.
24. Bjornstedt M, Hamberg M, Kumar S, Xue J, and Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 270: 11761-11764, 1995.
25. Black S, Harte EM, Hudson B, and Wartofsky L. A specific enzymatic reduction of 1(-) methionine sulfoxide and a related nonspecific reduction of disulfides. J Biol Chem 235: 2910-2916, 1960.
26. Blombäck B, Blombäck M, Finkbeiner W, Holmgren A, Kowalska-Loth B, and Olovson G. Enzymatic reduction of disulfide bonds in fibrinogen by the thioredoxin system. I. Identification of reduced bonds and studies on reoxidation process. Thrombosis Res 4: 55-57, 1974.
27. Bode AM and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
28. Brot N and Weissbach H. Biochemistry and physiological role of methionine sulfoxide residues in proteins. Arch Biochem Biophys 223: 271-281, 1983.
29. Bushweller JH, Åslund F, Ẅthrich K, and Holmgren A. Structural and functional characterization of the mutant Escherichia coli glutaredoxin (C14S) and its mixed disulfide with glutathione. Biochemistry 31: 9288-9293, 1992.
30. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, and Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth up-regulates thioredoxin-binding protein-2 and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705, 2002.
31. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, and Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 99: 9745-9749, 2002.
32. Casso D and Beach D. A mutation in a thioredoxin reductase gene homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet 252: 518-529, 1996.
33. Chrestensen CA, Starke DW, and Mieyal JJ. Acute cadmium exposure inactivates thioltransferase (glutaredoxin) inhibits intracellular reduction of protein-glutathionyl-mixed disulfides and initiates apoptosis. J Biol Chem 275: 26556-26565, 2000.
34. Clarke FM. Identification of molecules and mechanisms involved in the 'early pregnancy factor' system. Reprod Fertil Dev 4: 423-433, 1992.
35. Clarke FM, Orozco C, Perkins AV, Cock I, Tonissen KF, Robins AJ, and Wells JR. Identification of molecules involved in the 'early pregnancy factor' phenomenon. J Reprod Fertil 93: 525-539, 1991.
36. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjae A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, and Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis heart development and heart function. Mol Cell Biol 24: 9414-9423, 2004.
37. Daily D, Vlamis-Gardikas A, Offen D, Mittelmann L, Melamed E, Holmgren A, and Barzilai A. Glutaredoxin protects cerebellar granulae neurons from dopamine-induced apoptosis by dual activation of the Ras-phosphoinositide 3-kinase and Jun N-terminal kinase pathway. J Biol Chem 276: 21618-21626, 2001.
38. Daily D, Vlamis-Gardikas A, Offen D, Mittelmann L, Melamed E, Holmgren A, and Barzilai A. Glutaredoxin protects cerebellar granulae neurons from dopamine-induced apoptosis by activating NF-kappaB via Ref-1. J Biol Chem 276: 1335-1344, 2001.
39. Das KC, Guo XL, and White CW. Induction of thioredoxin and thioredoxin reductase gene expression in lungs of newborn primates by oxygen. Am J Physiol 276: L530-539, 1999.
40. Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JJ, and Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J Biol Chem 272: 25935-42590, 1997.
41. Dessein AJ, Lenzi HL, Bina JC, Carvalho EM, Weiser WY, Andrade ZA, and David JR. Modulation of eosinophil cytotoxicity by blood mononuclear cells from healthy subjects and patients with chronic schistosomiasis mansoni. Cell Immunol 85: 100-113, 1984.
42. Eklund H, Cambillau C, Sjöberg BM, Holmgren A, Jörnvall H, Höög JO, and Brändén CI. Conformational and functional similarites between glutaredoxin and thioredoxins. EMBO J 3: 1443-1449, 1984.
43. Engström NE, Holmgren A, Larsson A, and Söderhäll S. Isolation and characterization of calf liver thioredoxin. J Biol Chem 249: 205-210, 1974.
44. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, and Orrenius S. Overexpression of glutredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 327: 774-779, 2005.
45. Ericson ML, Horling J, Wendel-Hansen V, Holmgren A, and Rosen A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res 11: 201-207, 1992.
46. Fernandes AP and Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 6: 63-74, 2004.
47. Frand AR, Cuozzo JW, and Kaiser CA. Pathways for protein disulphide bond formation. Trends Cell Biol 10: 203-210, 2000.
48. Funato Y, Michiue T, Asashima M, and Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signaling through dishevelled. Nat Cell Biol 8: 501-508, 2006.
49. Ganther HE. Selenium metabolism selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20: 1657-1566, 1999.
50. Gasdaska PY, Gasdaska JR, Cochran S, and Powis G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett 373: 5-9, 1995.
51. Gasdaska PY, Oblong JE, Colgreave IA, and Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1218: 292-296, 1994.
52. Gatz SA and Wiesmuller L. p53 in recombination and repair. Cell Death Differ 13: 1003-1016, 2006.
53. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, and Trojanowski JQ. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48: 77-87, 2000.
54. Gladyshev VN, Jeang KT, and Stadtman TC. Selenocysteine identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 93: 6146-6151, 1996.
55. Gladyshev VN, Liu A, Novoselov SV, Krysan K, Sun QA, Kryukov VM, Kryukov GV, and Lou MF. Identification and characterization of a new mammalian glutaredoxin (thioltransferase) Grx2. J Biol Chem 276: 30374-30380, 2001.
56. Gravina SA and Mieyal JJ. Thioltransferase is a specific glutathionyl mixed disulfide oxidoreductase. Biochemistry 32: 3368-3376, 1993.
57. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, and Powis G. Thioredoxin a putative oncogene product is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31: 475-481, 2000.
58. Gromer S and Gross JH. Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase implications for the antitumor effects of selenium. J Biol Chem 277: 9701-9706, 2002.
59. Gromer S, Urig S, and Becker K. The thioredoxin system - from science to clinic. Med Res Rev 24: 40-89, 2004.
60. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, and Dimmler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 4: 743-749, 2002.
61. Hainaut P and Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53: 4469-4473, 1993.
62. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000.
63. Hansson HA, Holmgren A, Norstedt G, and Rozell B. Changes in the distribution of insulin-like growth factor I thioredoxin thioredoxin reductase and ribonucleotide reductase during the development of the retina. Exp Eye Res 48: 411-420, 1989.
64. Hansson HA, Holmgren A, Rozell B, and Stemme S. Localization of thioredoxin thioredoxin reductase and ribonucleotide reductase in cells: immunohistochemieal aspects. In: Thioredoxin and Glutaredoxin Systems Structure and Function, ed. by Holmgren A. New York, Raven Press, 1986, pp. 177-187.
65. Hansson HA, Rozell B, Stemme S, Engström Y, Thelander L, and Holmgren A. Different cellular distribution of thioredoxin and subunit M1 of ribonucleotide reductase in rat tissues. Exp Cell Res 163: 363-369, 1986.
66. Hariharan J, Hebbar P, Ranie J, Philomena Sinha AM, and Datta S. Alternative forms of the human thioredoxin mRNA: identification and characterization. Gene 173: 265-270, 1996.
67. Hashemy SI, Ungerstedt JS, Zahedi Avval F, and Holmgren A. Motexafin gadolinium a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697, 2006.
68. Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, and Tanaka H. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 25: 4035-4040, 1997.
69. Hayashi T, Uedo Y, and Okamato T. Oxidoreductive regulation of nuclear factor kappa-B Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268: 11380-11388, 1993.
70. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300, 1956.
71. Herrmann EC and Moore EC. Purification of thioredoxin from rat Novikoff ascites hepatoma. J Biol Chem 248: 1219-1223, 1973.
72. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94: 3633-3638, 1997.
73. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, and Yodoi J. Nucleoredoxin glutaredoxin and thioredoxin differentially regulate NF-kappaB AP-1 and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177-182, 2000.
74. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
75. Hofmann B, Hecht HJ, and Flohe L. Peroxiredoxins. Biol Chem 383: 347-364, 2002.
76. Holmgren A. Thioredoxin: 6 The amino acid sequence of the protein from Escherichia coli B. Eur J Biochem 6: 475-484, 1968.
77. Holmgren A. Thioredoxin: structure and functions. Trends in Biochem Sci 6: 26-28, 1981.
78. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966, 1989.
79. Holmgren A. Glutathione dependent synthesis of deoxyribonucleotides Characterization of the enzymatic mechanism of Escherichia coli glutaredoxin. J Biol Chem 327: 3672-3678, 1979.
80. Holmgren A. Hydrogen donor system for Escherichia coli ribonucleoside-diphosphate reductase dependent upon glutathione. Proc Natl Acad Sci USA 73: 2275-2279, 1976.
81. Holmgren A. Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. J Biol Chem 252: 4600-4606, 1977.
82. Holmgren A. Glutathione-dependent enzyme reactions of the phage T4 ribonucleotide reductase system. J Biol Chem 253: 7424-7430, 1978.
83. Holmgren A. Thioredoxin structure and mechanism: conformational change on oxidation of the active-site shulfhydryls to a disulfide. Structure 3: 239-243, 1995.
84. Holmgren A. Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action. J Biol Chem 254: 9113-9119, 1979.
85. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
86. Holmgren A and Morgan FJ. Enzymatic reduction of disulfide bonds by thioredoxin. The reactivity of disulfide bonds in human chorio-gonadotropin and its subunits. Eur J Biochem 70: 377-383, 1976.
87. Holmgren A, Ohlsson I and Grankvist M-L. Thioredoxin from Escherichia coli. Radioimmunological and enzymatic determinations in wild type cells and mutants defective in phage T7 DNA replication. J Biol Chem 253: 430-436, 1978.
88. Holmgren A, Söderberg BO, Eklund H, and Brändén CI. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 Ångström resolution. Proc Natl Acad Sci USA 72: 2305-2309, 1975.
89. Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H, and Yodoi J. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 168: 1027-1028, 2003.
90. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, and Gotoh Y. Induction of apoptosis by ASK1 a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94, 1997.
91. Iwai T, Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, and Yodoi J. Expression of adult T-cell leukaemia-derived factor a human thioredoxin homologue in the human ovary throughout the menstrual cycle. Virchows Arch A Pathol Anat Histopathol 420: 213-217, 1992.
92. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, and Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 25: 1980-1988, 2005.
93. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudathis S, and Prives C. Identification of redox/repair protein ref-1 as a potent activator of p53. Genes Dev 11: 558-570, 1997.
94. Jeng MF, Campbell AP, Begley T, Holmgren A, Case DA, Wright PE, and Dyson HJ. High-resolution solution structures of oxidized and reduced Escherichia coli thioredoxin. Structure 2: 853-868, 1994.
95. Jeong W, Yoon HW, Lee SR, and Rhee SG. Identification and characterization of TRP14 a thioredoxin-related protein of 14 kDa. New insights into the specificity of thioredoxin function. J Biol Chem 279: 3142-3150, 2004.
96. Jimenez A and Miranda-Vizuete A. Purification and characterization of delta3Trx-1 a splicing variant of human thioredoxin-1 lacking exon 3. Protein Expr Purif 27: 319-324, 2003.
97. Jimenez A, Zu W, Rawe VY, Pelto-Huikko M, Flickinger CJ, Sutovsky P, Gustafsson JA, Oko R, and Miranda-Vizuete A. Spermatocyte/spermatid-specific thioredoxin-3 a novel Golgi apparatus-associated thioredoxin is a specific marker of aberrant spermatogenesis. J Biol Chem 279: 34971-34978, 2004.
98. Johansson C, Lillig CH, and Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. J Biol Chem 279: 7537-7543, 2004.
99. Johnson GP, Goebel SJ, Perkus ME, Davis SW, Winslow JP, and Paoletti E. Vaccinia virus encodes a protein with similarity to glutaredoxins. Virology 181: 378-381, 1991.
100. Jordan A and Reichard P. Ribonucleotide reductases. Annu Rev Biochem 67: 71-98, 1998.
101. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, and Choi I. Vitamin D3 up-regulated protein I mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164: 6287-6295, 2000.
102. Kabe Y, Ando K, Hirao S, Yoshida M, and Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7: 395-403, 2005.
103. Kaghad M, Dessarps F, Jacquemin-Sablon H, Caput D, Fradelizi D, and Wollman EE. Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. Gene 140: 273-278, 1994.
104. Kallis GB and Holmgren A. Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from Escherichia coli. J Biol Chem 255: 10261-10265, 1980.
105. 3- or 2-mercaptoethanol. Proc Natl Acad Sci USA 86: 6018-6022, 1989.
106. 2 mixed-function oxidation system. J Biol Chem 263: 4704-4711, 1988.
107. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11: 8425-8430, 2005.
108. Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, and Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 65: 491-494, 2001.
109. Koc A, Mathews CK, Wheeler LJ, Gross MK, and Merrill GF. Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J Biol Chem 281: 15058-15063, 2006.
110. Krauth-Siegel RL and Coombs GH. Enzymes of parasite thiol metabolism as drug targets. Parasitol Today 15: 404-409, 1999.
111. Kruusma J, Benham AM, Williams JA, and Kataky R. An introduction to thiol redox proteins in the endoplasmic reticultum and a review of current electrochemical methods of detection of thiols. Analyst 131: 459-473, 2006.
112. Kumar S, Björnstedt M, and Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem 207: 435-439, 1992.
113. Kurooka H, Kato K, Minoguchi S, Takahashi Y, Ikeda J, Habu S, Osawa N, Buchberg AM, Moriwaki K, Shisa H, and Honjo T. Cloning and characterization of the nucleoredoxin gene that encodes a novel nuclear protein related to thioredoxin. Genomics 39: 331-339, 1997.
114. Laurent TC, Moore EC, and Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin the hydrogen donor from Escherichia coli. J Biol Chem 239: 3436-3444, 1964.
115. Lee K-K, Murakawa M, Takahashi S, Tsubuki S, Kawashima S, Sakamaki K, and Yonehara S. Purification molecular cloning and characterization of TRP32: a novel thioredoxin-related mammalian protein of 32 kDa. J Biol Chem 273: 19160-191664, 1998.
116. Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H, Lyu CY, Piao ZH, Kim SU, Han YH, Song SS, Lee YH, Song KS, Kim YM, Yu DY, and Choi I. VDUP1 is required for the development of natural killer cells. Immunity 22: 195-208, 2005.
117. Lee SR, Kim JR, Kwon KS, Yoon HW, Levine RL, Gindburg A, and Rhee SG. Molecular cloning and characterization of a mitochondrial selenocysteine- containing thioredoxin reductase from rat liver. J Biol Chem 274: 4722-4734, 1999.
118. Lenzi HL, Mednis AD, and Dessein AJ. Activation of human eosinophils by monokines and lymphokines: source and biochemical characteristics of the eosinophil cytotoxicity-enhancing activity produced by blood mononuclear cells. Cell Immunol 94: 333-346, 1985.
119. Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, and Sahel JA. Identification and characterization of rod-derived cone viability factor. Nat Genet 36: 755-759, 2004.
120. Levine RL, Moskovitz J, and Stadtman ER. Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation. IUBMB Life 50: 301-307, 2000.
121. Lillig CH, Berndt C, Vergnolle O, Lönn ME, Rudemann C, Bill E, and Holmgren A. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci USA 102: 8168-8173, 2005.
122. Lillig CH, Lönn ME, Enoksson M, Fernandes AP, and Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells towards doxorubicin and phenylarsine oxide. Proc Natl Acad Sci USA 101: 13227-13232, 2004.
123. Lippoldt A, Padilla CA, Gerst H, Andbjer B, Richter E, Holmgren A, and Fuxe K. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 15: 6747-6756, 1995.
124. Liu A, Arbiser JL, Holmgren A, Klein G, and Klein E. PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood 105: 1606-1613, 2005.
125. Liu W, Nakamura H, Shioji K, Tanito M, Oka S, Ahsan MK, Son A, Ishii Y, Kishimoto C, and Yodoi J. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 110: 1276-1283, 2004.
126. Liu Y and Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266, 2002.
127. Lou MF. Redox regulation in the lens. Prog Retin Eye Res 22: 657-682, 2003.
128. Lou MF. Thiol regulation in the lens. J Ocul Pharmacol Ther 16: 137-148, 2000.
129. Lovell MA, Xie C, Gabbita SP, and Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med 28: 418-427, 2000.
130. Lundberg M, Johansson C, Chandra J, Enoksson M, Jacobsson G, Ljung J, Johansson M, and Holmgren A. Cloning and expression of a novel human glutaredoxin (GRX2) with mitochodrial and nuclear isoforms. J Biol Chem 276: 26269-26275, 2001.
131. Lundström-Ljung J, and Holmgren A. Glutaredoxin accelerates glutathione-dependent folding of reduced ribonuclease A together with protein disulfide-isomerase. J Biol Chem 270: 7822-7828, 1995.
132. Makino Y, Okamoto K, Yoshikawa N, Aoshmia M, Hirota K, Yodoi J, Umesono K, Makino I, and Tanaka H. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 98: 2469-2477, 1996.
133. Mark DF and Richardson CC. Escherichia coli thioredoxin: a subunit of bacteriophage T7 DNA polymerase. Proc Natl Acad Sci USA 73: 780-784, 1976.
134. Martin JL. Thioredoxin - a fold for all reasons. Structure 3: 245-250, 1995.
135. Maruyama T, Kitaoka Y, Sachi Y, Nakanoin K, Hirota K, Shiozawa T, Yoshimura Y, Fujii S, and Yodoi J. Thioredoxin expression in the human endometrium during the menstrual cycle. Mol Hum Reprod 3: 989-993, 1997.
136. Masutani H, Bai J, Kim YC, and Yodoi J. Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Mol Neurobiol 29: 229-242, 2004.
137. Masutani H, Hirota K, Sasada T, Ueda-Taniguchi Y, Taniguchi Y, Sono H, and Yodoi J. Transactivation of an inducible antioxidative stress protein human thioredoxin by HTLV-1 Tax. Immunol Lett 54: 67-71, 1996.
138. Masutani H, Naito M, Takahashi K, Hattori T, Koito A, Takatsuki K, Go T, Nakamura H, Fujii S, Yoshida Y, Okuma M, and Yodoi J. Dysregulation of adult T-cell leukemia-derived factor (ADF)/thioredoxin in HIV infection: loss of ADF high-producer cells in lymphoid tissues of AIDS patients. AIDS Res Hum Retroviruses 8: 1707-1715, 1992.
139. Masutani H, Ueda S, and Yodoi J. The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ 12: 991-998, 2005.
140. Misui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
141. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, and Hay RT. Thioredoxin regulates the DNA binding activity of Nf-kappa-B by reducing a disulfide bond involving cysteine 62. Nucleic Acids Res 20: 3821-3830, 1992.
142. Meyer EB and Wells WW. Thioltransferase overexpression increases resistance of MCF-7 cells to adriamycin. Free Radic Biol Med 26: 770-776, 1999.
143. Miranda-Vizuete A, and Spyrou G. Genomic organization and identification of a novel alternative splicing variant of mouse mitochondrial thioredoxin reductase (TrxR2) gene. Mol Cells 13: 488-492, 2002.
144. Miranda-Vizuete A, Damdimopoulos AE, Pedrajas JR, Gustafsson JA, and Spyrou G. Human mitochondrial thioredoxin reductase cDNA cloning expression and genomic organization. Eur J Biochem 261: 405-412, 1999.
145. Miranda-Vizuete A, Gustafsson JÅ, and Spyrou G. Molecular cloning and expression of a cDNA encoding a human thioredoxin-like protein. Biochem Biophys Res Commun 243: 284-288, 1998.
146. Miranda-Vizuete A, Ljung J, Damdimopoulos AE, Gustafsson JA, Oko R, Pelto-Huikko M, and Spyrou G. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J Biol Chem 276: 31567-31574, 2001.
147. Miranda-Vizuete A, Sadek CM, Jimenez A, Krause WJ, Sutovsky P, and Oko R. The mammalian testis-specific thioredoxin system. Antioxid Redox Signal 6: 25-40, 2004.
148. Mitchell DA, and Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol 1: 154-158, 2005.
149. Mitsui A, Hamuro J, Nakamura H, Kondo N, Hirabayashi Y, Ishizaki-Koizumi S, Hirakawa T, Inoue T, and Yodoi J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4: 693-696, 2002.
150. Miura Y, Kano M, Abe K, Urano S, Suzuki S, and Toda T. Age-dependent variations of cell response to oxidative stress: proteomic approach to protein expression and phosphorylation. Electrophoresis 26: 2786-2796, 2005.
151. Molina-Navarro MM, Casas C, Piedrafita L, Belli G, and Herrero E. Prokaryotic and eukaryotic monothiol glutaredoxins are able to perform the functions of Grx5 in the biogenesis of Fe/S clusters in yeast mitochondria. FEBS Lett 580: 2273-2280, 2006.
152. Moon S, Fernando MR, and Lou MF. Induction of thioltransferase and thioredoxin/thioredoxin reductase systems in cultured porcine lenses under oxidative stress. Invest Ophthalmol Vis Sci 46: 3783-3789, 2005.
153. Moore EC. A thioredoxin-thioredoxin reductase system from rat tumor. Biochem Biophys Res Commun 29: 264-268, 1967.
154. Moore EC, Reichard P, and Thelander L. Enzymatic synthesis of deoxyribonucleotides, V. Purification and properties of thioredoxin reductase from Escherichia coli B. J Biol Chem 239: 3445-3452, 1964.
155. Mühlenhoff U, Gerber J, Richhardt N, and Lill R. Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J 22: 4815-4825, 2003.
156. Muller EG. Thioredoxin deficiency in yeast prolongs S phase and shortens the GI interval of the cell cycle. J Biol Chem 266: 9194-9202, 1991.
157. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y, and Yodoi J. Expression of thioredoxin and glutaredoxin redox regulating proteins in pancreatic cancer. Cancer Detect Prev 24: 53-60, 2000.
158. Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, Holmgren A, Herzenberg LA, and Herzenberg LA. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8: 603-611, 1996.
159. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA, and Herzenberg LA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98: 2688-2693, 2001.
160. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, Herzenberg LA, and Yodoi J. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 98: 15143-15148, 2001.
161. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, and Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69: 2091-2097, 1992.
162. Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T,
163. Nakamura H, Nakamura K, and Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369, 1997.
164. Nakamura T, Nakamura H, Hoshino T, Ueda S, Wada H, and Yodoi J. Redox regulation of lung inflammation by thioredoxin. Antioxid Redox Signal 7: 60-71, 2005.
165. Nakamura T, Ohno T, Hirota K, Nishiyama A, Nakamura H, Wada H, and Yodoi J. Mouse glutaredoxin-cDNA cloning high level expression in E. coli and its possible implication in redox regulation of the DNA binding activity in transcription factor PEBP2. Free Radic Res 31: 357-365, 1999.
166. Newman GW, Balcewicz-Sablinska MK, Guarnaccia JR, Remold HG, and Silberstein DS. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1. J Exp Med 180: 359-363, 1994.
167. Nikitovic D and Holmgren A. S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem 271: 19180-19185, 1996.
168. Nishinaka Y, Nishiyama A, Masutani H, Oka S, Ahsan KM, Nakayama Y, Ishii Y, Nakamura H, Maeda M, and Yodoi J. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res 64: 1287-1292, 2004.
169. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, and Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
170. Nonn L, Williams RR, Erickson RP, and Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis exencephaly and early embryonic lethality in homozygous mice. Mol Cell Biol 23: 916-922, 2003.
171. Nordstrom B, Randahl H, Slaby I, and Holmgren A. Characterization of bacteriophage T7 DNA polymerase purified to homogeneity by antithioredoxin immunoadsorbent chromatography. J Biol Chem 256: 3112-3117, 1981.
172. Ohira A, Honda O, Gauntt CD, Yamamoto M, Hori K, Masutani H, Yodoi J, and Honda Y. Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. Lab Invest 70: 279-285, 1994.
173. Okubo K, Kosaka S, Isowa N, Hirata T, Hitomi S, Yodoi J, Nakano M, and Wada H. Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung. J Thorac Cardiovasc Surg 113: 1-9, 1997
174. Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, Hirata KI, Kawashima S, Hayashi Y, Itoh H, Yodoi J, and Yokoyama M. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1483-1487, 2001.
175. Osborne LJ, Tonissen KF, Tang VH, and Clarke FM. Expression and localisation of thioredoxin in mouse reproductive tissues during the oestrous cycle. Mol Reprod Dev 58: 359-367, 2001.
176. Osborne SA, and Tonissen KF. Genomic organisation and alternative splicing of mouse and human thioredoxin reductase I genes. BMC Genomics 2: 10, 2001.
177. Osborne SA, Hawkes HJ, Baldwin BL, Alexander KA, Svingen T, Clarke FM, and Tonissen KF. The tert-butylhydroquinone-mediated activation of the human thioredoxin gene reveals a novel promoter structure. Biochem J 398: 269-277, 2006.
178. Park JB and Levine M. Cloning sequencing and characterization of alternatively spliced glutaredoxin I cDNA and its genomic gene: chromosomal localization mRNA stability and origin of pseudogenes. J Biol Chem 280: 10427-10434, 2005.
179. Parks D, Bolinger R, and Mann K. Redox state regulates binding of p53 to sequence-specific DNA but not to non-specific or mismatched DNA. Nucl Acid Res 25: 1289-1295, 1997.
180. Patenuade A, Murthy MRV, and Mirault ME. Emerging role of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci 62: 1063-1080, 2005.
181. Pearson GD and Merrill GF. Deletion of the Saccharomyces cerevisae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem 273: 5431-5434, 1998.
182. Pekkari K and Holmgren A. Truncated thioredoxin: physiological functions and mechanism. Antioxid Redox Signal 6: 53-61, 2004.
183. Pekkari K, Avila-Carino J, Bengtsson A, Gurunath R, Scheynius A, and Holmgren A. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood 97: 3184-3190, 2001.
184. Pekkari K, Goodarzi MT, Scheynius A, Holmgren A, and Avila-Carino J. Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38 ERK and JNK. Blood 105: 1598-1605, 2005.
185. Pekkari K, Gurunath R, Arner ES, and Holmgren A. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275: 37474-37480, 2000.
186. Peltoniemi M, Kaarteenaho-Wiik R, Saily M, Sormunen R, Paakko P, Holmgren A, Soini Y, and Kinnula VL. Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. Hum Pathol 35: 1000-1007, 2004.
187. Pineda-Molina E, Klatt P, Vazquez J, Martina A, de Lacoba MG, Perez-Sala D, and Lamas S. Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 40: 14134-14142, 2001.
188. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna PA, and Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77: 7415-7419, 1980.
189. Potamitou A, Holmgren A, and Vlamis-Gardikas A. Protein levels of Escherichia coli thioredoxins and glutaredoxins and their relation to null mutants growth phase and function. J Biol Chem 277: 18561-18567, 2002.
190. Powis G and Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41: 261-295, 2001.
191. Qin J, Clore GM, and Gronenborn AM. The high-resolution three-dimensional solution structures of the oxidized and reduced states of human thioredoxin. Structure 2: 503-522, 1994.
192. Rahman I, Biswas SK, and Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 533: 222-239, 2006.
193. Rajagopal I, Ahn BY, Moss B, and Mathews CK. Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis. J Biol Chem 270: 27415-27418, 1995.
194. Rhee SG, Chae HY, and Kim K. Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
195. Rhee SG, Kang SW, Netto LE, Seo MS, and Stadtman ER. A family of novel peroxidases, peroxiredoxins. Biofactors 10: 207-209, 1999.
196. Rodriguez-Manzaneque MT, Ros J, Cabiscol E, Sorribas A, and Herrero E. Grx5 glutaredoxin plays a central role in protection against protein oxidative damage in Saccharomyces cerevisiae. Mol Cell Biol 19: 8180-8190, 1999.
197. Rodriguez-Manzaneque MT, Tamarit J, Belli G, Ros J, and Herrero E. Grx5 is a mitochondrial glutaredoxin required for the activity of iron/sulfur enzymes. Mol Biol Cell 13: 1109-1121, 2002.
198. Rohrbach S, Gruenler S, Teschner M, and Holtz J. The thioredoxin system in aging muscle: key role of mitochondrial thioredoxin reductase in the protective effects of caloric restriction? Am J Physiol Regul Integr Comp Physiol 291: R927-R935, 2006.
199. Royds JA and Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 13: 1017-1026, 2006.
200. Rozell B, Barcena JA, Martinez-Galisteo E, Padilla CA, and Holmgren A. Immunochemical characterization and tissue distribution of glutaredoxin (thioltransferase) from calf. Eur J Cell Biol 62: 314-323, 1993.
201. Rozell B, Hansson HA, Luthman M, and Holmgren A. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur J Cell Biol 38: 79-86, 1985.
202. Rubartelli A, Bajetto A, Allavena G, Wollman E, and Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 24161-24164, 1992.
203. Rundlöf AK, Janard M, Miranda-Vizuete A, and Arnér ES. Evidence for intriguingly complex transcription of human thioredoxin reductase I. Free Radic Biol Med 36: 641-656, 2004.
204. Russel M and Model P. The role of thioredoxin in filamentous phage assembly. Construction isolation and characterization of mutant thioredoxins. J Biol Chem 261: 14997-15005, 1986.
205. Rybnikova E, Damdimopoulos AE, Gustafsson JA, Spyrou G, and Pelto-Huikko M. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci 12: 1669-1678, 2000.
206. Sadek CM, Damdimopoulos AE, Pelto-Huikko M, Gustafsson JA, Spyrou G, and Miranda-Vizuete A. Sptrx-2 a fusion protein composed of one thioredoxin and three tandemly repeated NDP-kinase domains is expressed in human testis germ cells. Genes Cells 6: 1077-1091, 2001.
207. Sadek CM, Jiminez A, Damdimopoulos AE, Kieselbach T, Nord M, Gustafsson JA, Spyrou G, Davies EC, Oko R, van der Hoorn FA, and Miranda-Vizuete A. Characterization of human thioredoxin-like 2 A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme. J Biol Chem 278: 13133-13142, 2003.
208. Sahlin L, Ostlund E, Wang H, Holmgren A, and Fried G. Decreased expression of thioredoxin and glutaredoxin in placentae from pregnancies with pre-eclampsia and intrauterine growth restriction. Placenta 21: 603-609, 2000.
209. Sahlin L, Stjernholm Y, Holmgren A, Ekman G, and Eriksson H. The expression of thioredoxin mRNA is increased in the human cervix during pregnancy. Mol Hum Reprod 3: 1113-1117, 1997.
210. Sahlin L, Wang H, Stjernholm Y, Lundberg M, Ekman G, Holmgren A, and Eriksson H. The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately postpartum particularly after prostaglandin-induced delivery. Mol Hum Reprod 6: 1147-1153, 2000.
211. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) I. EMBO J 17: 2596-2606, 1998.
212. Sanz A, Pamplona R, and Barja G. Is the mitochondrial free radical theory of aging intact? Antioxid Redox Signal 8: 582-599, 2006.
213. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, and Yodoi J. Free in PMC redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97: 2268-2276, 1996.
214. Schenk H, Vogt M, Dröge W, and Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol 156: 765-771, 1996.
215. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, and Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409, 2002.
216. Shioji K, Nakamura H, Masutani H, and Yodoi J. Redox regulation by thioredoxin in cardiovascular diseases. Antioxid Redox Signal 5: 795-802, 2003.
217. Silberstein DS, Ali MH, Baker SL, and David JR. Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics and partial amino acid sequence of an active polypeptide. J Immunol 143: 979-983, 1989.
218. Silberstein DS, Dessein AJ, Elsas PP, Fontaine B, and David JR. Characterization of a factor from the U937 cell line that enhances the toxicity of human eosinophils to Schistosoma mansoni larvae. J Immunol 138: 3042-3050, 1987.
219. Silberstein DS, McDonough S, Minkoff MS, and Balecwicz-Sablinska MK. Human eosinophil cytotoxicity-enhancing factor. Eosinophil-stimulating and dithiol reductase activities of biosynthetic (recombinant) species with COOH-terminal deletions. J Biol Chem 268: 9138-9142, 1993.
220. Smeyne RJ and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134: 57-66, 2005.
221. Song JJ and Lee YJ. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase I. Biochem J 373: 854-853, 2003.
222. 2. J Biol Chem 277: 46566-46575, 2002.
223. Spyrou G, Enmark E, Miranda-Vizuete A, and Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272: 2936-2941, 1997.
224. Srinivasan U, Mieyal PA, and Mieyal JJ. pH profiles indicative of rate-limiting nucleophilic displacement in thioltransferase catalysis. Biochemistry 36: 3199-3206, 1997.
225. Stadtman ER, van Remmen H, Richardson A, Wehr NB, and Levine RL. Methionine oxidation and aging. Biochem Biophys Acta 1703: 135-140, 2005.
226. Stemme S, Hansson HA, Holmgren A, and Rozell B. Axioplasmic transport of thioredoxin and thioredoxin reductase in rat sciatic nerve. Brain Res 359: 140-146, 1985.
227. Stryer L, Holmgren A, and Reichard P. Thioredoxin. A localized conformational change accompanying reduction of the protein to the sulfhydryl form. Biochemistry 6: 1016-1020, 1967.
228. Su D and Gladyshev VN. Alternative splicing involving the thioredoxin reductase module in mammals: a glutaredoxin-containing thioredoxin reductase 1. Biochemistry 43: 12177-12188, 2004.
229. Su D, Novoselov SV, Sun QA, Moustafa ME, Zhou Y, Oko R, Hatfield DL, and Gladyshev VN. Mammalian selenoprotein thioredoxin-glulathione reductase. Roles in disulfide bond formation and sperm maturation. J Biol Chem 280: 26491-26498, 2005.
230. Sun QA, Kirnarskydagger L, Shermandagger S, and Gladyshev VN. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci USA 98: 3673-3678, 2001.
231. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi M, and Yodoi J. ATL-derived factor (ADF) an IL-2 receptor/Tac inducer homologous to thioredoxin: possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8: 757-764, 1989.
232. Takagi Y, Gon Y, Todaka T, Nozaki K, Nishiyama A, Sono H, Hashimoto N, Kikuchi H, and Yodoi J. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Lab Invest 78: 957-966, 1998.
233. Takagi Y, Horikawa F, Nozaki K, Sugino T, Hashimoto N, and Yodoi J. Expression and distribution of redox regulatory protein thioredoxin during transient focal brain ischemia in the rat. Neurosci Lett 251: 25-28, 1998.
234. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96: 4134-4136, 1999.
235. Takagi Y, Nakamura T, Nishiyama A, Nozaki K, Tanaka T, Hashimoto N, and Yodoi J. Localization of glutaredoxin (thioltransferase) in the rat brain and possible functional implications during focal ischemia. Biochem Biophys Res Commun 258: 390-394, 1999.
236. Takagi Y, Tokime T, Nozaki K, Gon Y, Kikuchi H, and Yodoi J, Redox control of neuronal damage during brain ischemia after middle cerebral artery occlusion in the rat: immunohistochemical and hybridization studies of thioredoxin. J Cereb Blood Flow Metab 8: 206-214, 1998.
237. Takashima Y, Hirota K, Nakamura H, Nakamura T, Akiyama K, Cheng FS, Maeda M, and Yodoi J. Differential expression of glutaredoxin and thioredoxin during monocytic differentiation. Immunol Lett 68: 397-401, 1999.
238. Tamura T and Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification properties and thioredoxin reductase activity. Proc Natl Acad Sci USA 93: 1006-1011, 1996.
239. Taniguchi Y, Taniguchi-Ueda Y, Mori K, and Yodoi J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res 24: 2746-2752, 1996.
240. Tanito M, Masutani H, Nakamura H, Oka S, Ohira A, and Yodoi J. Attenuation of retinal photooxidative damage in thioredoxin transgenic mice. Neurosci Lett 326: 142-146, 2002.
241. Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch WJ, Feelisch M, and Ma XL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation. Proc Natl Acad Sci USA 101: 11471-11476, 2004.
242. Teshigawara K, Maeda M, Nishino K, Nikaido T, Uchiyama T, Tsudo M, Wano Y, and Yodoi J. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 2: 17-26, 1985.
243. Thelander L and Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 48: 133-158, 1979.
244. Tiitto L, Kaarteenaho-Wiik R, Sormunen R, Holmgren A, Paakko P, Soini Y, and Kinnula VL. Expression of the thioredoxin system in interstitial lung disease. J Pathol 201: 363-370, 2003.
245. Tomimoto H, Akiguchi I, Wakita H, Kimura J, Hori K, and Yodoi J. Astroglial expression of ATL-derived factor a human thioredoxin homologue in the gerbil brain after transient global ischemia. Brain Res 625: 1-8, 1993.
246. Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, and Das DK. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 35: 695-704, 2003.
247. Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, and Soini Y. Thioredoxin is associated with proliferation p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 112: 123-132, 2004.
248. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, and Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481-492, 1977.
249. Ueda S, Nakamura T, Yamada A, Teratani A, Matsui N, Furukawa S, Hoshino Y, Narita M, Yodoi J, and Nakamura H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci 79: 1170-1179, 2006.
250. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, and Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
251. Ueno M, Matsutani Y, Nakamura H, Masutani H, Yagi M, Yamashiro H, Kato H, Inamoto T, Yamauchi A, Takahashi R, Yamaoka Y, and Yodoi J. Possible association of thioredoxin and p53 in breast cancer. Immunol Lett 75: 15-20, 2000.
252. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005.
253. Vanderlelie J, Venardos K, Clifton VL, Gude NM, Clarke FM, and Perkins AV. Increased biological oxidation and reduced antioxidant enzyme activity in pre-eclamptic placentae. Placenta 26: 53-58, 2005.
254. Wahlgren CM and Pekkari K. Elevated thioredoxin after angioplasty in peripheral arterial disease. Eur J Vasc Endovasc Surg 29: 281-286, 2005.
255. Weichsel A, Gasdaska JR, Powis G, and Montfort WR. Crystal structures of reduced oxidized and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 4: 735-751, 1996.
256. Wells WW, Xu DP, Yang YF, and Rocque PA. Mammalian thioltransferase (glutaredoxin) and protein disulfide isomerase have dehydroascorbate reductase activity. J Biol Chem 265: 15361-15364, 1990.
257. Welsh SJ, Bellamy WT, Brichl MM, and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095, 2002.
258. White CL, Senkevich TG, and Moss B. Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J Virol 76: 467-472, 2002.
259. Wilson LG, Asahi T, and Bandurski RS. Yeast sulfate-reducing system. 1. Reduction of sulfate to sulfite. J Biol Chem 236: 1822-1829, 1961.
260. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, Tübingen Screen Consortium, and Zon LI. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436: 1035-1039, 2005.
261. Witte AB, Anestål K, Jerremalm E, Ehrsson H, and Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39: 696-703, 2005.
262. Witte S, Villalba M, Bi K, Liu Y, Isakov N, and Altman A. Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem 275: 1902-1909, 2000.
263. Wollman EE, d'Auriol L, Rimsky L, Shaw A, Jacquot JP, Wingfield P, Graber P, Dessarps F, Robin P, and Galibert F. Cloning and expression of a cDNA for human thioredoxin. J Biol Chem 263: 15506-15512, 1988.
264. Wood-Allum CA, Barber SC, Kirby J, Heath P, Holden H, Mead R, Higginbottom A, Allen S, Beaujeux T, Alexson SE, Inee PG, and Shaw PJ. Impairment of mitochondrial anti-oxidant defence in SODI-related motor neuron injury and amelioration by ebselen. Brain 129: 1693-1709, 2006.
265. Xanthoudakis S and Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J 11: 653-665, 1992.
266. Xanthoudakis S, Miao GG, and Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci USA 91: 23-27, 1994.
267. Yamada Y, Nakamura H, Adachi T, Sannohe S, Oyamada H, Kayaba H, Yodoi J, and Chihara J. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol Lett 86: 199-205, 2003.
268. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vamer SF, and Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112: 1395-1406, 2003.
269. Yamanaka H, Machira F, Oshiro M, Asato T, Yanagawa Y, Takei H, and Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271: 796-800, 2000.
270. Yamawaki H, Haendeler J, and Berk BC. Thioredoxin: A key regulator of cardiovascular homeostasis. Circ Res 93: 1029-1033, 2003.
271. Yang Y, Jao S, Nanduri S, Starke DW, Mieyal JJ, and Qin J. Reactivity of the human thioltransferase (glutaredoxin) C7S C25S C78S C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity. Biochemistry 37: 17145-17156, 1998.
272. Yodoi J, Takatsuki K, and Masuda T. Letter: two cases of T-cell chronic lymphocytic leukemia in Japan. N Engl J Med 290: 572-573, 1974.
273. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, and Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin and etoposide. Cancer Res 55: 4293-4296, 1995.
274. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, and Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281: 13005-13008, 2006.
275. Yoshida T, Nakamura H, Masutani H, and Yodoi J. The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann NY Acad Sci 1055: 1-12, 2005.
276. Yoshida T, Oka S, Masutani H, Nakamura H, and Yodoi J. The role of thioredoxin in the aging process: involvement of oxidative stress. Antioxid Redox Signal 5: 563-570, 2003.
277. Zhao R and Holmgren A. A novel antioxidant mechanism of ebselen involving ebselen diselenide a substrate of mammalian thioredoxin and thioredoxin reductase. J Biol Chem 277: 39456-39462, 2002.
278. Zhao R, Masayasu H, and Holmgren A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci USA 99: 8579-8584, 2002.
279. Zhong L and Holmgren A. Essential role of selenium in the catalytic activities of thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 275: 18121-18128, 2000.
280. Zhong L, Arnér ESJ, and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redoxactive selenolthiol/selenylsulfide formed from the conserved cysteine-selenocystine sequence. Proc Natl Acad Sci USA 97: 5854-5859, 2000.
281. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, and Smith MA. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 31: 205-217, 2005.